Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus Pre-conditioning for Bispecific Antibodies in Multiple Myeloma
NCT07581704Phase 1Recruiting
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sirolimus in multiple myeloma (MM). Primary endpoints: Dose Limiting Toxicities and Teffector to Texhausted cell ratio at 3 months. Started Jun 2026; status: recruiting.
02
Drugs
sirolimus
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07581704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581704.